Trial Profile

A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Miransertib (Primary)
Indications Proteus syndrome
Focus Therapeutic Use

Most Recent Events

13 Mar 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Mar 2026.
23 May 2022 Planned initiation date (estimated date for recruitment of the first subject) changed to 29 May 2022.
26 Apr 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Apr 2022 to 2 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com